Benzinga | Jun 4, 2021 09:22AM EDT

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl's CLN-081 in NSCLC EGFR Exon 20 Patients

* CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity Profile

* As of the Data Cutoff, No Grade 3 TRAE Diarrhea at Doses Below 150mg BID; No Grade 3 Rash TRAEs

* Objective Responses Were Observed Across the Dose Range, with a Confirmed Objective Response Rate of 46% in Patients Treated at 100 mg BID

* Phase 2a Expansion Initiated at 100 mg BID